RECURSION PHARMACEUTICALS IN's ticker is RXRX and the CUSIP is 75629V104. A total of 201 filers reported holding RECURSION PHARMACEUTICALS IN in Q4 2023. The put-call ratio across all filers is 0.72 and the average weighting 1.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $74,902,725 | -27.5% | 9,987,030 | -3.6% | 0.06% | -22.5% |
| Q1 2024 | $103,317,146 | +13.8% | 10,362,803 | +12.6% | 0.07% | +6.0% |
| Q4 2023 | $90,749,271 | +236.7% | 9,203,780 | +161.2% | 0.07% | +204.5% |
| Q3 2023 | $26,951,899 | +330.9% | 3,523,124 | +320.7% | 0.02% | +340.0% |
| Q2 2023 | $6,255,378 | +86.8% | 837,400 | +66.8% | 0.01% | +150.0% |
| Q1 2023 | $3,348,187 | -4.5% | 501,977 | +10.4% | 0.00% | -33.3% |
| Q4 2022 | $3,504,365 | -32.9% | 454,522 | -7.4% | 0.00% | -25.0% |
| Q3 2022 | $5,221,000 | +60.4% | 490,740 | +22.7% | 0.00% | +33.3% |
| Q2 2022 | $3,255,000 | -48.5% | 399,901 | +8.4% | 0.00% | -25.0% |
| Q4 2021 | $6,321,000 | -32.9% | 368,994 | -9.8% | 0.00% | -33.3% |
| Q3 2021 | $9,416,000 | +20.8% | 409,194 | +91.6% | 0.01% | +20.0% |
| Q2 2021 | $7,797,000 | – | 213,608 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kinnevik AB (publ) | 11,905,668 | $89,292,510 | 100.00% |
| DCVC Opportunity Fund II GP, LLC | 3,951,141 | $29,633,558 | 44.95% |
| Data Collective IV GP, LLC | 5,941,120 | $44,558,400 | 31.23% |
| NVIDIA CORP | 7,706,363 | $57,797,723 | 14.70% |
| MIC Capital Management UK LLP | 8,451,758 | $63,388,186 | 13.78% |
| ARK Investment Management | 28,142,918 | $211,071,885 | 1.87% |
| RA Capital Management | 15,384,615 | $115,384,613 | 1.53% |
| COMMONS CAPITAL, LLC | 111,107 | $833,302 | 1.00% |
| ELEVATUS WELATH MANAGEMENT | 342,567 | $2,569,253 | 0.96% |
| Lingotto Investment Management LLP | 3,675,077 | $27,563,078 | 0.93% |